Cellular Biomedicine's Stock Surges After Company Receives Strategic Investment

Shares of Cellular Biomedicine Group Inc CBMG, a biomedical company that is engaged in the development of new treatments for cancerous and degenerative diseases, surged higher by more than 6 percent on Thursday. Cellular Biomedicine announced on Thursday it has received a $43.13 million investment from Wuhan Dangdai Science & Technology Industries Group for 2.27 million shares of the company's stock. The agreed upon price per share was $19, representing a 10.4 percent premium over Wednesday's closing price. "We appreciate the huge vote of confidence from DANGDAI. We are delighted that such an astute, established conglomerate with a major pharmaceutical presence is making this strategic investment in CBMG. Their pharmaceutical portfolio company has a large direct sales force in China with access to thousands of hospitals. The funding will augment resources for our long-term clinical trials in stem cell indications and multiple T-cell Chimeric Antigen Receptor ("CAR-T") trials in liquid and solid tumor cancers," said Tony (Bizuo) Liu, incoming Chief Executive Officer (current CFO) of CBMG.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsBiomedical CompaniesCancer TreatmentCellular BiomedicineDegenerative DiseasesTony LiuWuhan Dangdai Science & Technology
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!